AccessibilityHelp
PolyPid logo

PolyPid(NASDAQ) PYPD

Market Cap$107.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-98%
1 Year+54%
1 Month+1%
$5.29
+0.76%
+0.04Today
PolyPid last closing stock price
MetricPriceDate
Last closeUSD 5.292026-10-26
PolyPid stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.4%USD 4.882026-10-19
1 month+1.34%USD 5.222026-09-25
3 month+41.07%USD 3.752026-07-28
Year to date+21.89%USD 4.342025-12-31
1 year+53.78%USD 3.442025-10-24
3 year+39.95%USD 3.782023-10-27
5 year-97.57%USD 217.952021-10-27
Since inception-99.08%USD 570.002020-06-26

PolyPid Financials at a Glance

Market Cap

$107.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$31.50M

EPS (TTM)

-$1.48

P/E Ratio

-3.57

Dividend

$0.00

Beta (Volatility)

0.92 (Low)

Price

$5.29

Volume

96,685

Open

$5.25

Previous Close

$5.29

Daily Range

$5.17 - $5.37

52-Week Range

$3.50 - $5.73

Estimated Earnings Date

Nov 11, 2026

PYPD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PolyPid

PolyPid Ltd. is an advanced-stage biopharmaceutical company focused on developing therapeutic solutions using its proprietary polymer-lipid encapsulation matrix (PLEX) platform. The company aims to address significant unmet medical needs, with its leading product candidate, D-PLEX100, currently in Phase III clinical trials for preventing surgical site infections.

Products and Services
  • D-PLEX100: A product candidate for preventing surgical site infections
  • Proprietary PLEX platform for drug delivery
  • Focus on unmet medical needs in surgical settings
Growth Outlook
  • Phase III trials for D-PLEX100 could lead to market entry
  • Strong pipeline with potential for additional product candidates
  • Increasing demand for innovative surgical solutions in healthcare
Financial Highlights
  • Recent quarterly net income of -$7.85 million
  • Cash and cash equivalents of $6.56 million as of June 30, 2026
  • Operating expenses of $7.85 million in Q2 2026
PolyPid Ltd. operates in the biotechnology sector, emphasizing innovative solutions for surgical procedures. The company's flagship product, D-PLEX100, is positioned to meet a critical need in preventing infections, which is a significant concern in surgical environments. The ongoing Phase III trials represent a pivotal moment for the company, potentially leading to commercialization and revenue generation. Financially, PolyPid has faced challenges, as indicated by recent net losses. However, the company maintains a solid cash position, which is crucial for funding ongoing research and development efforts. The focus on unmet medical needs and the potential for market entry with D-PLEX100 could provide significant growth opportunities in the future. As the healthcare landscape evolves, PolyPid's innovative approach may position it favorably within the biotechnology industry.
AI Generated • Oct 20, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

75

CEO

Dikla Czaczkes Akselbrad, MBA, CPA

Website

www.polypid.com

Headquarters

Petah Tikva, HM 4959376, IL

PYPD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-311.07%

Return on Capital

-239.43%

Return on Assets

-206.78%

Earnings Yield

-28.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$107.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

20.31M

Volume

96.69K

Avg. Volume

122.17K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$1.16M

EBITDA

-$29.69M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$6.56M

Total Debt

$1.57M

PolyPid Performance Analysis

PolyPid annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
PolyPid sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
PolyPid annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.04-10.5%
20232023-12-31USD -16.99734.6%
20242024-12-31USD -4.91-71.1%
20252025-12-31USD -2.09-57.4%
PolyPid sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3052.6%
Q42025-12-31-10.8%
Q12026-03-3114.6%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$107.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.49M

N/A

Employees

72

N/A

Net Income

-$7.85M

+21.3%

EBITDA

-$7.46M

+20.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$6.56M

-77.7%

Total Debt

$1.57M

-81.9%

Accounts Receivable

$0.00

N/A

Inventory

$1.36M

N/A

Long Term Debt

$282.00K

-73.2%

Short Term Debt

$1.29M

-83.1%

Return on Assets

-2.07%

N/A

Return on Invested Capital

13.49%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PDSBPDS Biotechnology Corporation
$1.07-4.05%
ANVSAnnovis Bio, Inc.
$0.96-4.23%
VERUVeru Inc.
$2.21-1.34%
CELUCelularity Inc.
$0.75-23.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.59-16.95%
EWZiShares - iShares Msci Brazil ETF
$34.15-19.82%
ITUBItaú Unibanco
$7.70-20.37%
XPXP
$15.71-48.36%

Questions About PYPD

What is the current price of PolyPid?

PolyPid is trading at $5.29 per share.

What is the 52-week range for PolyPid?

Over the past 52 weeks, PolyPid has traded between $3.50 and $5.73.

How much debt does PolyPid have?

As of the most recent reporting period, PolyPid reported total debt of $1.57M.

How much cash does PolyPid have on hand?

PolyPid reported $6.77M in cash and cash equivalents in its most recent financial results.

What is PolyPid’s dividend yield?

PolyPid does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services